Table 2 Demographic, comorbidity, prescription drug use characteristics of people who died of overdose during follow-up, by substance use type.
From: Concurrent use of opioids and stimulants and risk of fatal overdose: A cohort study
| Ā | Stimulant use only N(%) | Opioid use only N(%) | Both N(%) | Total N(%) | P value |
|---|---|---|---|---|---|
87 (32Ā·0) | 74 (27Ā·2) | 111 (40Ā·8) | 272(100Ā·0) | ||
Demographics | |||||
Sex | |||||
āFemale | 22(25Ā·3) | 21(28Ā·4) | 32(28Ā·8) | 75(27Ā·6) | 0Ā·340 |
āMale | 65(74Ā·7) | 53(71Ā·6) | 79(71Ā·2) | 197(72Ā·4) | Ā |
Age | |||||
āā<ā30 | 21(24Ā·1) | 24(32Ā·4) | 25(22Ā·5) | 70(25Ā·7) | 0Ā·170 |
ā30-39 | 14(16Ā·1) | 13(17Ā·6) | 29(26Ā·1) | 56(20Ā·6) | Ā |
ā40-49 | 28(32Ā·2) | 13(17Ā·6) | 30(27Ā·0) | 71(26Ā·1) | Ā |
ā50+ | 24(27Ā·6) | 24(32Ā·4) | 27(24Ā·3) | 75(27Ā·6) | Ā |
Health Authority Region | |||||
āFraser | 26(30Ā·0) | 25(33Ā·8) | 21(18Ā·9) | 72(26Ā·5) | 0Ā·007 |
āInterior | 17(19Ā·5) | 13(17Ā·6) | 18(16Ā·2) | 48(17Ā·6) | Ā |
āNorthern | 5(5Ā·6) | ā | 5(4Ā·5) | 14(5Ā·1) | Ā |
āVancouver Coastal | 25(28Ā·7) | 16(21Ā·6) | 56(50Ā·5) | 97(35Ā·7) | Ā |
āVancouver Island | 14(16Ā·1) | 16(21Ā·6) | 11(9Ā·9) | 41(15Ā·1) | Ā |
Comorbidities | |||||
Elixhauser index | |||||
ā0 | 19(21Ā·8) | 34(45Ā·9) | 28(25Ā·2) | 81(29Ā·8) | 0Ā·013 |
ā1 | 21(24Ā·1) | 15(20Ā·3) | 20(18Ā·0) | 56(20Ā·6) | Ā |
ā2 | 19(21Ā·8) | 7(9Ā·5) | 22(19Ā·8) | 48(17Ā·6) | Ā |
ā3+ | 28(32Ā·3) | 18(24Ā·3) | 41(36Ā·9) | 87(32Ā·0) | Ā |
Prescribed medications (Prior 30ādays at baseline) | |||||
āBenzodiazepines | 15(17Ā·2) | 15(20Ā·3) | 19(17.1) | 49(18Ā·0) | 0Ā·839 |
āZ drugs | 8(9Ā·2) | 5(6Ā·8) | 12(10.8) | 25(9Ā·2) | 0Ā·646 |
āSedatives | 48(55Ā·2) | 52(70Ā·3) | 71(64.0) | 171(62Ā·9) | 0Ā·135 |
āOpioid for pain | 18(20Ā·7) | 16(21Ā·6) | 24(21.6) | 58(21Ā·3) | 0Ā·985 |